Blog | Veristat Insights

Understanding Why Creative Solutions Are Necessary

With last month’s celebration of Rare Disease Month and specifically, Rare Disease Day, awareness of the research challenges faced by patients and pharma companies are especially high during this season.

If you heard the phrase, “You have cancer,” what would be your response?

In pharmaceutical clinical trials, considering competing risk analyses is highly important. Competing risks are events that may occur and prevent the evaluation of a specific primary endpoint, in turn biasing risk estimations or drug efficacy. 

To Improve Real-Time Visibility of Clinical Trial Documentation and Inspection-Readiness

Veristat has completed the validation and configuration of Master Control’s eTMF system, which is now implemented and available for Veristat managed clinical trials. 

Last week, Veristat attended the Massachusetts Biotechnology Council (MassBio) forum titled “Evolution of an Academic Discovery: First Person Account of the Development of Velcade®”.   

On Saturday, February 4, Team Veristat joined the battle against rare cancers at the 2017 Cycle for Survival event! Team Veristat had 14 riders at the Boston, MA event, including 2 colleagues from our UK office.  Our team surpassed our goal of raising over $25,000 to fund rare cancer research!

For anyone who follows this blog with even moderate consistency, it is probably clear that Veristat is a growing organization.  It is hopefully just as apparent that we are a group who tremendously values and fiercely protects our culture. 

Read more about this and the discussions that you missed at the MassBio Forum on Adaptive Designs in Clinical Research that took place last month.